{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:24:41Z","timestamp":1784615081976,"version":"3.55.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jcf.2020.07.014","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T02:41:35Z","timestamp":1595990495000},"page":"506-510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Biliary disease and cholecystectomy after initiation of elexacaftor\/ivacaftor\/tezacaftor in adults with cystic fibrosis"],"prefix":"10.1016","volume":"20","author":[{"given":"Julie","family":"Safirstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Savant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Dezube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.jcf.2020.07.014_bib0001","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jcf.2017.07.006","article-title":"Gallbladder and bile duct disease in cystic fibrosis","volume":"16","author":"Assis","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2020.07.014_bib0002","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-2007-1007159","article-title":"Liver and biliary problems in cystic fibrosis","volume":"18","author":"Colombo","year":"1998","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10.1016\/j.jcf.2020.07.014_bib0003","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11894-005-0053-6","article-title":"The gallbladder and biliary tract in cystic fibrosis","volume":"7","author":"Curry","year":"2005","journal-title":"Curr Gastroenterol Rep"},{"issue":"3","key":"10.1016\/j.jcf.2020.07.014_bib0004","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrgastro.2015.226","article-title":"Cystic fibrosis from the gastroenterologist's perspective","volume":"13","author":"Ooi","year":"2016","journal-title":"Nat Rev Gastroeneterol Hepatol"},{"issue":"3","key":"10.1016\/j.jcf.2020.07.014_bib0005","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MOG.0b013e3283298865","article-title":"Hepatobiliary disease in patients with cystic fibrosis","volume":"25","author":"Moyer","year":"2009","journal-title":"Curr Opin Gastronenterol"},{"issue":"3","key":"10.1016\/j.jcf.2020.07.014_bib0006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/SLE.0b013e318219a2b5","article-title":"Postoperative outcomes and quality of life in patients with cystic fibrosis undergoing laparoscopic cholecystectomy: a retrospective study","volume":"21","author":"Cogliandolo","year":"2011","journal-title":"Surg Laparosc Endosc Percutan Tech"},{"issue":"1","key":"10.1016\/j.jcf.2020.07.014_bib0007","first-page":"35","article-title":"Treatment and prognosis of symptomatic gallbladder disease in patients with cystic fibrosis","volume":"5","author":"Stern","year":"1986","journal-title":"J Pediatr Gastronenterol Nutr"},{"issue":"6","key":"10.1016\/j.jcf.2020.07.014_bib0008","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0002-9610(89)90698-3","article-title":"Operative therapy of gallbladder disease in patients with cystic fibrosis","volume":"157","author":"Snyder","year":"1989","journal-title":"Am J Surg"},{"issue":"2","key":"10.1016\/j.jcf.2020.07.014_bib0009","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/BF02944189","article-title":"Laparoscopic cholecystectomy in adult cystic fibrosis patients","volume":"166","author":"McGrath","year":"1997","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.jcf.2020.07.014_bib0010","year":"2019"},{"key":"10.1016\/j.jcf.2020.07.014_bib0011","doi-asserted-by":"crossref","unstructured":"Middleton PG, Mall MA, Drevinek P, et\u00a0al. Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele. [published online October 31, 2019]. N Engl J Med. 2019; 381(19): 1809\u20131819. doi:10.1056\/NEJMoa1908639.","DOI":"10.1056\/NEJMoa1908639"},{"key":"10.1016\/j.jcf.2020.07.014_bib0012","doi-asserted-by":"crossref","unstructured":"Heijerman HG, McKone EF, Downey DG, et\u00a0al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial [published online October 31, 2019]. Lancet. 2019; 394: 1940\u20131948. doi:10.1016\/S0140-6736(19)32597-8.","DOI":"10.1016\/S0140-6736(19)32597-8"},{"issue":"6","key":"10.1016\/j.jcf.2020.07.014_bib0013","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/0016-5085(93)91085-V","article-title":"Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells","volume":"105","author":"Cohn","year":"1993","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jcf.2020.07.014_bib0014","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cld.2018.12.008","article-title":"Hepatic manifestations of cystic fibrosis","volume":"23","author":"Sakiani","year":"2019","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jcf.2020.07.014_bib0015","unstructured":"Cystic Fibrosis Foundation Patient Registry. Annual Data Report; 2018. Bethesda, Maryland."},{"key":"10.1016\/j.jcf.2020.07.014_bib0016","unstructured":"US Food and Drug Administration. Multi-discipline review: trikafta (elexacaftor\/tezacaftor\/ivacaftor) tablet (Application No. 212273Orig1s000). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212273Orig1s000Approv.pdf"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320308067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320308067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:44:20Z","timestamp":1761601460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199320308067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1569199320308067"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2020.07.014","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biliary disease and cholecystectomy after initiation of elexacaftor\/ivacaftor\/tezacaftor in adults with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2020.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}